PNK: ADTX
Aditxt, Inc.
Healthcare · Biotechnology
Per-share valuation inputs need verification
Event dated Mar 31, 2026Market-derived shares outstanding and recent statement shares differ materially. Per-share ratios and valuation outputs may be unreliable until the share base is verified. This sometimes appears with ADRs or provider share-count gaps.
Market Cap
$2.99M
52w High
$31,364.28
52w Low
$0.00
P/E
-0.00
Volume
12.52M
Outstanding Shares
997.98M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 100% over the last year. Revenue declined 74.09% over the trailing twelve months. Operating margin moved from -39,651.08% to -127,821.37%. Free cash flow grew 17.49% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -127,821.37%. Revenue declined 74.09% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques.
Valuation
Stock splits
Every 27 shares became 1
Every 8 shares became 1
Every 113 shares became 1
Every 250 shares became 1
Every 40 shares became 1
Every 40 shares became 1
Every 50 shares became 1
Profitability & growth
Analyst consensus
1
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Sep 2, 2026
Q3 FY26 · EPS est -$24,408,000,000.00 · Revenue est $1M
View